Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics, Inc. reports developments in rare-disease biopharmaceuticals, with recurring updates on FILSPARI (sparsentan), FDA regulatory actions, commercialization in IgA nephropathy and focal segmental glomerulosclerosis, and financial results. The company focuses on therapies for rare kidney, liver, and metabolic diseases, including sparsentan and the investigational enzyme replacement therapy pegtibatinase.
Company news also covers clinical data presentations, partner-related regulatory and commercial milestones for sparsentan, capital-structure activity, inducement equity grants under Nasdaq rules, and investor-conference participation.
Travere Therapeutics (Nasdaq: TVTX) reported that on July 10, 2026, its Board Compensation Committee approved Nasdaq Rule 5635(c)(4) inducement equity grants for six new employees, totaling 41,600 shares, split into 18,000 stock options and 23,600 RSUs with four-year vesting schedules.
Travere Therapeutics (Nasdaq: TVTX) announced that chief research officer William Rote, Ph.D. plans to retire in February 2027 after 10 years. Jula Inrig, M.D., current CMO, will become executive vice president, head of research and development and CMO, assuming oversight of the broader R&D organization.
Travere Therapeutics (Nasdaq: TVTX) granted inducement restricted stock units (RSUs) to six new employees on June 10, 2026, covering an aggregate of 32,000 common shares.
The RSUs, granted under Nasdaq Listing Rule 5635(c)(4), vest over four years, with 25% vesting annually, subject to continued service.
Travere Therapeutics (Nasdaq: TVTX) presented long-term open-label extension data from the Phase 3 DUPLEX study of FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS) at the 63rd ERA 2026 Congress.
Patients maintained durable, clinically meaningful proteinuria reductions for up to approximately five years with a safety profile generally consistent with prior findings.
Travere Therapeutics (Nasdaq: TVTX) entered an exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib, an investigational covalent reversible BTK inhibitor for immune-mediated rare kidney diseases, in all markets outside China and certain East/Southeast Asian countries.
According to Travere, Everest receives a $112.5 million upfront payment, up to about $1.03 billion in milestones across up to five indications, plus tiered royalties. Civorebrutinib has Phase 1/2 proof-of-concept data in primary membranous nephropathy and is planned for evaluation in FSGS, minimal change disease and other indications.
Travere Therapeutics (Nasdaq: TVTX) received a Notice of Allowance from the USPTO for U.S. Patent Application No. 19/253,088 covering certain methods of using FILSPARI (sparsentan) in IgA nephropathy.
Upon issuance, the patent is expected to provide U.S. method-of-use protection into October 2037, and Travere plans to submit it for FDA Orange Book listing.
Travere Therapeutics (Nasdaq: TVTX) granted inducement equity awards on May 10, 2026 to four new employees, covering an aggregate of 48,800 shares of common stock. Grants include 18,000 stock options at $43.51 per share and 30,800 RSUs, issued under Nasdaq Listing Rule 5635(c)(4).
Travere Therapeutics (Nasdaq: TVTX) will present at three investor conferences in May–June 2026: BofA Securities Health Care (May 13, 2026, 5:20 p.m. ET), Jefferies Global Healthcare (June 3, 2026, 8:45 a.m. ET) and Goldman Sachs 47th Annual Global Healthcare (June 8, 2026, 11:20 a.m. ET).
Live webcasts and replays (available for up to 30 days) will be on Travere’s investor events page: ir.travere.com/events-and-presentations.
Travere Therapeutics (Nasdaq: TVTX) priced an upsized offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032, expected to close May 11, 2026. Travere estimates net proceeds of approximately $460.0 million (or $508.5 million if over-allotment exercised).
About $350.9 million of net proceeds are intended to repurchase approximately $221.4 million aggregate principal of outstanding 2.25% convertible notes due 2029; remaining proceeds for general corporate purposes including commercialization, clinical R&D, capex, and working capital.
Travere (Nasdaq: TVTX)/b) intends to offer
The Notes will be senior unsecured, accrue interest semiannually, and be convertible into cash, common stock, or both. Repurchases depend on negotiations; hedged holders may buy common stock concurrently, potentially affecting market price and effective conversion price. Joint book-runners: J.P. Morgan, Jefferies, Leerink. Registration on Form S-3 filed 08/01/2024.